1. Home
  2. PRTC vs AVIR Comparison

PRTC vs AVIR Comparison

Compare PRTC & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$17.45

Market Cap

400.2M

Sector

Health Care

ML Signal

HOLD

Logo Atea Pharmaceuticals Inc.

AVIR

Atea Pharmaceuticals Inc.

HOLD

Current Price

$5.50

Market Cap

450.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRTC
AVIR
Founded
2015
2012
Country
United States
United States
Employees
90
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
400.2M
450.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PRTC
AVIR
Price
$17.45
$5.50
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
5.2K
262.4K
Earning Date
04-29-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.00
EPS
N/A
N/A
Revenue
N/A
$351,367,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.09
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.50
$2.46
52 Week High
$19.92
$6.45

Technical Indicators

Market Signals
Indicator
PRTC
AVIR
Relative Strength Index (RSI) 50.73 48.38
Support Level $16.60 $3.28
Resistance Level $18.34 $6.37
Average True Range (ATR) 0.55 0.22
MACD -0.03 -0.05
Stochastic Oscillator 19.48 39.67

Price Performance

Historical Comparison
PRTC
AVIR

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Share on Social Networks: